Similar Search Results

Woo, Jean; Cockram, Clive - In: Disease Management and Health Outcomes 8 (2000) 1, pp. 29-41

With increasing chronic disease and disability burden as a result of the aging of populations worldwide, cost estimates of disease and disability are important in determining: 1. the most cost-effective methods in delivering healthcare in order to maximise resources; and 2. health policies and...

Persistent link: https://www.econbiz.de/10005448788

Adolfsson, Jan - In: PharmacoEconomics 21 (2003) 4, pp. 241-247

Health-related quality of life (HR-QOL) research, in general, is developing. It is becoming increasingly recognised as being important and knowledge on how to assess HR-QOL is spreading. Modern HR-QOL research should assess prevalence and severity of symptoms or functions, as well as the bother...

Persistent link: https://www.econbiz.de/10005449039

Treatment of Atopic Dermatitis and Impact on Quality of Life: A Review with Emphasis on Topical Non-Corticosteroids

Schiffner, Roman; Schiffner-Rohe, Julia; Landthaler, Michael - In: PharmacoEconomics 21 (2003) 3, pp. 159-179

review the present literature is analysed concerning impact on quality of life for topically-applicable alternatives to the … increase in impact on quality of life. Since studies used different QOL measurements and vary in inclusion criteria, treatment … active treatment modalities and their impact on quality of life. Consensus meetings are desirable to formulate guidelines for …

Persistent link: https://www.econbiz.de/10005449047

Quality-of-Life Assessment in Comparative Therapeutic Trials and Causal Structure Considerations in Peripheral Occlusive Arterial Disease

Lehert, Philippe - In: PharmacoEconomics 19 (2001) 2, pp. 121-130

When considering the use of quality of life as a primary end-point in phase III to IV comparative trials, the trial designer generally faces some unresolved questions. These include: How does one explain that some dimensions [quality-of-life (QOL) instruments usually have more than 1 dimension]...

Persistent link: https://www.econbiz.de/10005449116

Reporting Heterogeneity in the Measurement of Health and Health-Related Quality of Life

Shmueli, Amir - In: PharmacoEconomics 20 (2002) 6, pp. 405-412

Objective: To investigate heterogeneity (systematic and observable variation) in health or health-related quality-of-life reports across population groups, for a given level of `true health'. Design: The investigators undertook full sit-down face-to-face interviews with 1999 individuals...

Persistent link: https://www.econbiz.de/10005449133

Arpinelli, Fabio; Visona, Giovanni; Bruno, Raffaele; … - In: PharmacoEconomics 18 (2000) 1, pp. 63-72

Objective: To investigate the psychometric performance and clinical validity of the 36-Item Short Form (SF-36) health survey when completed by asymptomatic HIV-positive Italian patients and to compare their health profile with a representative sample of 2031 Italian citizens (the Italian norm)....

Persistent link: https://www.econbiz.de/10005449147

International Validation of the CLAU-S Quality-of-Life Questionnaire for Use in Patients with Intermittent Claudication

Marquis, Patrick; Comte, Sylvie; Lehert, Philippe - In: PharmacoEconomics 19 (2001) 6, pp. 667-677

Background: Intermittent claudication (IC) occurs in patients with peripheral occlusive arterial disease and results in leg pain after walking a certain distance - the claudication distance. Until recently, no specific questionnaire has been available to measure quality of life in patients with...

Persistent link: https://www.econbiz.de/10005449179

Apolone, Giovanni; De Carli, Gianfranco; Brunetti, Massimo - In: PharmacoEconomics 19 (2001) 2, pp. 187-195

Interest in measuring qualitative aspects of life that are most closely related to health and healthcare has increased in recent years. Methods of describing patients' subjective health status now incorporate standardised measures, and several psychometric measures are available. Despite the...

Persistent link: https://www.econbiz.de/10005449180

A Multinational Study to Measure the Value that Patients with Cancer Place on Improved Emesis Control Following Cisplatin Chemotherapy

Dranitsaris, George; Leung, Pauline; Ciotti, Renoto; … - In: PharmacoEconomics 19 (2001) 9, pp. 955-967

Background: The neurokinin-1 (NK1) receptor antagonists are a new class of agents designed to reduce the risk of emesis following chemotherapy, particularly with cisplatin. Early data from double-blind randomised trials suggest that an orally administered NK1 antagonist can reduce the absolute...

Persistent link: https://www.econbiz.de/10005449201

A Meta-Analysis of Quality-of-Life Estimates for Stroke

Tengs, Tammy O.; Lin, Ting H. - In: PharmacoEconomics 21 (2003) 3, pp. 191-200

Background: Researchers performing cost-effectiveness analyses often incorporate quality-of-life (QOL) estimates. Objective: To aid analysts, we performed a meta-analysis to estimate quality of life for minor, moderate, and major stroke and assessed the relative importance of study design...

Persistent link: https://www.econbiz.de/10005449208